Methotrexate: Difference between revisions

Line 30: Line 30:
*Hepatotoxicity
*Hepatotoxicity
*Nephrotoxicity
*Nephrotoxicity
*Myelosuppression, aplastic anemia, pancytopenia
*Myelosuppression, [[aplastic anemia]], [[pancytopenia]]
*Infectious disease
*Infectious disease
*Tumor lysis syndrome
*[[Tumor lysis syndrome]]
*GI bleed
*[[GI bleed]]
*Neurotoxicity, seizure
*Neurotoxicity, [[seizure]]
*Pericardial effusion
*[[Pericardial effusion]]
*TEN
*[[TEN]]
===Common===
===Common===
*Nausea/vomiting, diarrhea
*[[Nausea/vomiting]], [[diarrhea]]
*Stomatitis
*Stomatitis
*Leukopenia, thrombocytopenia
*[[Leukopenia]], [[thrombocytopenia]]
*Alopecia, photosensitivity, rash
*Alopecia, photosensitivity, [[rash]]
*Dizziness
*[[Dizziness]]
 
==Pharmacology==
==Pharmacology==
*Half-life: 8-15hr
*Half-life: 8-15hr

Revision as of 21:03, 3 October 2016

Administration

  • Type: Immunosuppressant/antineoplastic
  • Dosage Forms:
  • Routes of Administration: IV/IM, oral
  • Common Trade Names:

Adult Dosing

Ectopic pregnancy

  • Single-dose regimen: Methotrexate 50 mg/m2

Pediatric Dosing

Special Populations

Renal Dosing

  • Adult:
  • Pediatric:

Hepatic Dosing

  • Adult:
  • Pediatric:

Contraindications

  • Allergy to class/drug
  • Breastfeeding, pregnant, or possibility of impregnating someone
  • Blood dyscrasias
  • Chronic liver disease

Adverse Reactions

Serious

Common

Pharmacology

  • Half-life: 8-15hr
  • Metabolism: Extensive hepatic and intracellular
  • Excretion: Mostly renal. Dialyzable.

Mechanism of Action

  • Inhibits dihydrofolate reductase--> blocks DNA synthesis and thus, cellular replication/repair

Comments

See Also

References